|Podcasts|April 11, 2022

Dr. Sebesta on the role of social determinants of health in urology

“The social needs aren't medical conditions that can be alleviated in a doctor's office, and they shouldn't be medicalized or viewed in that way,” says Elisabeth M. Sebesta, MD.

In this episode, Urology Times® Assistant Editor Janelle Hart spoke with Elisabeth M. Sebesta, MD, about the study, “Patients with urologic conditions are more likely to have unmet social needs,” which was given at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction 2022 Winter Meeting. Sebesta is a female pelvic medicine and reconstructive surgery fellow in the department of urology at Vanderbilt University in Nashville, Tennessee.

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Latest CME

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Jeremie Calais, MD, PhD; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

Dr. Sebesta on the role of social determinants of health in urology

Related Content

The UroOnc Minute: Variant Histologies in Bladder Cancer, With Carissa Chu, MD

Pearls & Perspectives: The Evolving Landscape of Female Pelvic Health, With Annah J. Vollstedt, MD

The UroOnc Minute: MDT for Oligometastatic Prostate Cancer, with Chad Tang, MD

Pearls & Perspectives: Expanding Options for Men With Erectile Dysfunction, With Tom Riester

Pearls & Perspectives: Understanding the Peptide Movement in Men’s Health, with Larry I. Lipshultz, MD

Latest CME

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Radioligand Therapy 101: The Science Behind the Strategy

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Community Practice Connections™: Beyond the Basics— Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Trending on Urology Times

Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC

Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring

FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC

ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer

FDA approves adjuvant belzutifan with pembrolizumab for ccRCC